Patents Assigned to SANIONA A/S
  • Tesofensine and metoprolol for treatment of hypertension
    Patent number: 12178810
    Abstract: The present invention relates to treatment of hypertension using a combination of tesofensine and metoprolol. The treatment is particularly well suited for the treatment of hypertensive obese subjects and hypertensive diabetic subjects.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: December 31, 2024
    Assignee: Saniona A/S
    Inventors: Berit Edsberg, Thomas Amos Jacobsen
  • Tesofensine and beta blocker combination formulations
    Patent number: 12016840
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: June 25, 2024
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Potassium channel inhibitors
    Patent number: 12006289
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: June 11, 2024
    Assignee: Saniona A/S
    Inventors: David Tristram Brown, Palle Christophersen, Thomas Amos Jacobsen, Janus S. Larsen, Pernille Hartveit Poulsen, Dorte Strøbaek
  • Tesofensine and beta blocker combination formulations
    Patent number: 11426383
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: August 30, 2022
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • GABAA receptor ligand
    Patent number: 11396510
    Abstract: The present invention relates to 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol, which is useful as a GABA receptor modulator. In one embodiment, said compound is useful in the treatment of pain, neuropathic pain and/or itch.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: July 26, 2022
    Assignee: Saniona A/S
    Inventors: Janus S. Larsen, Dipak Amrutkar, Thomas Amos Jacobsen, Tino Dyhring, Karin Sandager Nielsen
  • Tesofensine and beta blocker combination formulations
    Patent number: 10828278
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: November 10, 2020
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Tesofensine and beta blocker combination formulations
    Patent number: 10537551
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: January 21, 2020
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Tesofensine, beta blocker combination formulation
    Patent number: 10231951
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: March 19, 2019
    Assignee: SANIONA A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • TESOFENSINE AND METOPROLOL FOR TREATMENT OF HYPERTENSION
    Publication number: 20190060301
    Abstract: The present invention relates to treatment of hypertension using a combination of tesofensine and metoprolol. The treatment is particularly well suited for the treatment of hypertensive obese subjects and hypertensive diabetic subjects.
    Type: Application
    Filed: December 30, 2016
    Publication date: February 28, 2019
    Applicant: Saniona A/S
    Inventors: Berit EDSBERG, Thomas Amos JACOBSEN
  • Tesofensine compositions
    Patent number: 9949964
    Abstract: The present invention relates to tesofensine compositions, methods to prepare the same and uses thereof in preparing medicines for the prevention and treatment of overweight, obesity and type 2 diabetes mellitus.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: April 24, 2018
    Assignee: Saniona A/S
    Inventor: Bruno Racheboeuf
  • Phenyl triazole derivative and its use for modulating the GABAreceptor complex
    Patent number: 9931329
    Abstract: Phenyl triazole derivative (specifically, 1-[6-[[5-(2-fluorophenyl)-3-methyl-triazol-4-yl]methoxy]-3-pyridyl]imidazole-4-carbonitrile or a pharmaceutically acceptable salt thereof), pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: April 3, 2018
    Assignee: SANIONA A/S
    Inventors: Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen
  • Phenyl triazole derivative and its use for modulating the GABAreceptor complex
    Patent number: 9884848
    Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: February 6, 2018
    Assignee: Saniona A/S
    Inventors: Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen
  • Tesofensine and beta blocker combination formulations
    Patent number: 9579288
    Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: February 28, 2017
    Assignee: Saniona A/S
    Inventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
  • Tetrazole derivatives and their use as potassium channel modulators
    Patent number: 9556132
    Abstract: A tetrazole derivative of general formula (I), a pharmaceutical composition comprising said compound and its use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: January 31, 2017
    Assignee: Saniona A/S
    Inventors: Joachim Demnitz, Susanne Jorgensen
  • Phenyl triazole derivative and its use for modulating the GABAreceptor complex
    Patent number: 9475797
    Abstract: This invention relates to a novel phenyl triazole derivative, pharmaceutical compositions containing this compound, and methods of treatment therewith. The compound of the invention is in particular considered useful for the treatment of central nervous system diseases and disorders which are responsive to modulation of GABAA receptors containing the ?5 subunit.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: October 25, 2016
    Assignee: Saniona A/S
    Inventors: Janus Schreiber Larsen, Magnus Gustafsson, Carsten Jessen
  • Method for combating adverse effects arising from antipsychotic treatment
    Patent number: 9457018
    Abstract: This invention relates to a method for combating adverse effects arising from antipsychotic treatment. The invention furthermore relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a compound of formula I and an antipsychotic drug.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: October 4, 2016
    Assignee: Saniona A/S
    Inventors: Jørgen Scheel-Krüger, Henrik Björk Hansen
  • Pharmaceutical compositions for combination therapy
    Patent number: 9387184
    Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 12, 2016
    Assignee: Saniona A/S
    Inventors: Henrik Bjork Hansen, Morten Grunnet, Bo Hjorth Bentzen, Lars Hyveled-Nielsen, Jorgen Buus Lassen, Claus Sundgreen
  • Pharmaceutical compositions for combination therapy
    Patent number: 9211271
    Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: December 15, 2015
    Assignee: SANIONA A/S
    Inventors: Henrik Björk Hansen, Morten Grunnet, Bo Hjorth Bentzen, Lars Hyveled-Nielsen, Jørgen Buus Lassen, Claus Sundgreen